Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

D. Hlauschek · SciRah

Researcher profile · Semantic Scholar

D. Hlauschek

Share profile

D. Hlauschek — researcher profile on SciRah

h-index: 11
Works: 78
Citations: 511

Most-cited papers

Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
C. Saura, D. Hlauschek, M. Oliveira, D. Zardavas +22 more
2019The Lancet Oncology87 citations
Semantic Scholar
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
I. Šestak, Miguel Martín, P. Dubsky, R. Kronenwett +11 more
2019Breast Cancer Research and Treatment86 citations Open access
Semantic Scholar
Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only
M. Filipits, P. Dubsky, M. Rudas, R. Greil +10 more
2019Clinical Cancer Research79 citations
Semantic Scholar
Randomized clinical trial of the effect of a fibrin sealant patch on pancreatic fistula formation after pancreatoduodenectomy
M. Schindl, R. Függer, P. Götzinger, F. Längle +6 more
2018British Journal of Surgery47 citations Open access
Semantic Scholar
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
E. Mayer, C. Fesl, D. Hlauschek, L. García-Estévez +29 more
2022Journal of Clinical Oncology28 citations Open access
Semantic Scholar
LBA10_PRPrimary results of LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole (LET) plus taselisib versus LET plus placebo (PLA) in postmenopausal patients (pts) with ER+/HER2-negative early breast cancer (EBC)
C. Saura, E. de Azambuja, D. Hlauschek, M. Oliveira +16 more
201722 citations Open access
Semantic Scholar
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6
M. Filipits, M. Rudas, C. Singer, F. Fitzal +13 more
2021ESMO Open20 citations Open access
Semantic Scholar
Impact of BMI in Patients With Early Hormone Receptor–Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial
G. Pfeiler, D. Hlauschek, E. Mayer, C. Deutschmann +47 more
2023Journal of Clinical Oncology19 citations
Semantic Scholar
Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study
Samer El Kababji, Nicholas Mitsakakis, Elizabeth Jonker, A. Beltran-Bless +18 more
2025Journal of Medical Internet Research16 citations Open access
Semantic Scholar
Palbociclib with adjuvant endocrine therapy in early breast cancer: five-year follow up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).
E. Mayer, D. Hlauschek, M. Gnant, P. O'Brien +36 more
2025Annals of Oncology13 citations Open access
Semantic Scholar
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial
G. Rinnerthaler, D. Egle, R. Bartsch, C. Schmitt +26 more
2025Nature Cancer11 citations Open access
Semantic Scholar
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.
A. Beltran-Bless, M. Clemons, C. Fesl, Richard Greil +19 more
2022European Journal of Cancer9 citations
Semantic Scholar
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)
G. Nader-Marta, C. Singer, D. Hlauschek, A. DeMichele +17 more
2024Breast Cancer Research8 citations Open access
Semantic Scholar
Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)
E. Agostinetto, G. Pfeiler, D. Hlauschek, E. Mayer +16 more
2025ESMO Open6 citations Open access
Semantic Scholar
The future of clinical trials—goals, ideas, and discussion
M. Gnant, Manuela Gili, Magdalena Schwarz, C. Fesl +3 more
2024memo - Magazine of European Medical Oncology6 citations Open access
Semantic Scholar
Addition of the MUC-1 vaccine tecemotide to neoadjuvant systemic therapy for patients with early breast cancer: Survival results from the prospective randomized ABCSG 34 trial.
C. Singer, D. Hlauschek, G. Pfeiler, D. Egle +14 more
2024Journal of Clinical Oncology5 citations
Semantic Scholar
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
A. Demichele, A. Dueck, D. Hlauschek, M. Martin +31 more
2025Breast Cancer Research4 citations Open access
Semantic Scholar
Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
K. Wimmer, D. Hlauschek, M. Balić, G. Pfeiler +14 more
2024Breast Cancer Research and Treatment4 citations Open access
Semantic Scholar
Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.
G. Pfeiler, D. Hlauschek, E. Mayer, C. Deutschmann +16 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar
HER2 and HER3 expression during neoadjuvant treatment of HER2‐negative early breast cancer: potential for biomarker‐driven sequencing of T‐DXd and HER3‐DXd
C. Singer, S. Jahn, D. Hlauschek, Ulrike M. Heber +25 more
2025Cancer Communications3 citations Open access
Semantic Scholar
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor–Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8
M. Filipits, M. Rudas, Verena Kainz, C. Singer +15 more
2021Clinical Cancer Research3 citations
Semantic Scholar
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial
D. Egle, D. Hlauschek, S. Gampenrieder, G. Rinnerthaler +17 more
2026npj Breast Cancer2 citations Open access
Semantic Scholar
Integrating baseline ctDNA-derived tumor metrics enhances risk stratification in HR-positive/HER2-negative advanced breast cancer: a real-world multicenter cohort study from Austria
N. Dobrić, S. Hasenleithner, C. Suppan, E. Klocker +14 more
2026ESMO Open2 citations Open access
Semantic Scholar
A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials
S. Potter, Kerry Avery, R. Ahmed, J. de Boniface +337 more
2025npj Breast Cancer2 citations Open access
Semantic Scholar
The impact of analysis methodology details on invasive breast cancer-free survival in randomized clinical trials
D. Hlauschek, C. Fesl, M. Gnant
2025ESMO Open2 citations
Semantic Scholar
Prospective randomized phase II trial to assess the efficacy and safety of neo-adjuvant olaparib/carboplatin (OC) in comparison to docetaxel/epirubicin/cyclophosphamide (TAC) in patients with early triple-negative breast cancer (TNBC) with homologous recombination deficiency (HRD): Primary results f
C. Singer, D. Hlauschek, D. Egle, Z. Bagó-Horváth +16 more
2025Journal of Clinical Oncology2 citations
Semantic Scholar
ESR1, PGR, ERBB2, and MKi67 mRNA expression in diagnostic core biopsies from breast cancer patients of the ABCSG Trial 34
S. Kacerovsky-Strobl, C. Deutschmann, D. Hlauschek, Z. Bagó-Horváth +17 more
2025Breast2 citations Open access
Semantic Scholar
Abstract GS03-07: Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer
D. Stover, D. Hlauschek, E. Mayer, W. Symmans +20 more
2024Cancer Research2 citations
Semantic Scholar
Standardized Definitions for Efficacy End Points for Adjuvant Trials-The Updated STEEP Criteria.
D. Hlauschek, C. Fesl, M. Gnant
2024JAMA Oncology2 citations
Semantic Scholar
123O Randomized phase II trial of neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in early HER2-positive breast cancer (ABCSG-52/ATHENE)
G. Rinnerthaler, D. Egle, R. Bartsch, C. Schmitt +16 more
2023ESMO Open2 citations Open access
Semantic Scholar
Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial.
P. Nuciforo, D. Hlauschek, C. Saura, E. de Azambuja +16 more
2019Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract P4-08-05: Prediction of distant recurrence using EndoPredict among women with ER-positive, HER2-negative breast cancer with a maximum follow-up of 16 years
M. Filipits, P. Dubsky, M. Rudas, R. Greil +9 more
2019Poster Session Abstracts2 citations
Semantic Scholar
Abstract PD11-01: Development of a Multi-Modal Artificial Intelligence (MMAI) Model for Predicting Distant Metastasis in HR+ Early-Stage Invasive Breast Cancer
C. Geyer, D. Kates-Harbeck, P. Rastogi, R. Kates +23 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Common analysis pitfalls in longitudinal ctDNA studies: lead time, sensitivity and immortal time bias
D. Hlauschek, N. Dandachi, M. Gnant, Heather A. Parsons +4 more
2026EBioMedicine1 citations Open access
Semantic Scholar
Abstract RF3-04: Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial
H. A. Parsons, K. Ballman, E. Heitzer, M. Watson +25 more
2026Clinical Cancer Research1 citations
Semantic Scholar
Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2− breast cancer: insights and implications
E. Klocker, N. Dobrić, R. Graf, C. Beichler +12 more
2025npj Breast Cancer1 citations Open access
Semantic Scholar
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
M. Naughton, D. Zahrieh, M. Gnant, N. Zdenkowski +38 more
2025ESMO Open1 citations Open access
Semantic Scholar
Abstract PS3-03: Vaccination with MUC-1-targeting tecemotide improves Survival of patients receiving neo-adjuvant chemotherapy for early breast cancer: Results from the Prospective Randomized ABCSG 34 Trial
C. Singer, D. Hlauschek, G. Pfeiler, D. Egle +15 more
2025Clinical Cancer Research1 citations
Semantic Scholar
Validation of the CTS5 in four prospective, multicenter, randomized ABCSG trials
K. Wimmer, D. Hlauschek, M. Balić, G. Pfeiler +14 more
2025Breast1 citations Open access
Semantic Scholar
Commentary on “Prognosis according to the timing of recurrence in breast cancer” (Ann Surg Treat Res 2023;104:1-9)
D. Hlauschek, M. Gnant
2024Annals of Surgical Treatment and Research1 citations Open access
Semantic Scholar
Abstract P4-10-01: Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05)
M. Naughton, D. Zahrieh, M. Gnant, N. Zdenkowski +37 more
2022Cancer Research1 citations
Semantic Scholar
Adjuvant palbociclib for ER+ breast cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort
A. DeMichele, A. Dueck, D. Hlauschek, Miguel Martín +16 more
2022Journal of Clinical Oncology1 citations
Semantic Scholar
Abstract RF7-07: Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall Survival
A. Demichele, A. Dueck, M. Gnant, D. Hlauschek +26 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial.
C. Dauccia, M. Franzoi, C. Saura, D. Hlauschek +12 more
2026European Journal of Cancer0 citations
Semantic Scholar
Abstract PS2-07-11: The improved long-term outcome in denosumab-treated postmenopausal women with early luminal breast cancer in Abcsg 18 is driven by progesterone receptor-positive tumors
C. Singer, D. Hlauschek, D. Egle, A. Reiner +18 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer
E. Shinn, D. Zahrieh, A. DeMichele, N. Zdenkowski +39 more
2026Breast Cancer Research and Treatment0 citations
Semantic Scholar
Abstract PS2-07-21: Tumor Necrosis Factor-related Weak Inducer of Apoptosis (TWEAK) - A Potential Biomarker for Predicting Response and Long-Term Outcomes in Early Breast Cancer Patients
K. Wimmer, D. Hlauschek, A. Rauch, M. Sachet +16 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract PS3-11-06: Long-term prognostic and predictive value of lobular histology in the PALLAS trial
G. Nader-Marta, C. Desmedt, D. Hlauschek, A. Demichele +22 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract PS3-04-08: Independent Validation of a Pathology-Based Multimodal Artificial Intelligence Biomarker for Predicting Risk of Distant Metastasis in Postmenopausal, Estrogen Receptor-Positive, Early-Stage Breast Cancer Patients: Analysis of the ABCSG Trial 8
M. Filipits, D. Hlauschek, J. Zhang, M. Balić +17 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract RF3-03: Evaluation of a digital pathology based multimodal artificial intelligence model for prognosis and prediction of chemotherapy benefit in node-negative, hormone receptor-positive breast cancer patients: analysis of the NSABP B-20 trial
C. Geyer, M. Filipits, N. Harbeck, J. Zhang +12 more
2026Clinical Cancer Research0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Balić×27
Invite
M. Balić — researcher profile on SciRah
C. Fesl×25
Invite
C. Fesl — researcher profile on SciRah
G. Pfeiler×20
Invite
G. Pfeiler — researcher profile on SciRah
M. Gnant×18
Invite
M. Gnant — researcher profile on SciRah

×14

Invite

M. Gnant — researcher profile on SciRah

Invite

D. Egle — researcher profile on SciRah

Z. Bagó-Horváth×13

Invite

Z. Bagó-Horváth — researcher profile on SciRah

G. Rinnerthaler×13

Invite

G. Rinnerthaler — researcher profile on SciRah

Invite

F. Fitzal — researcher profile on SciRah

Invite

C. Singer — researcher profile on SciRah

A. DeMichele×10

Invite

A. DeMichele — researcher profile on SciRah

M. Filipits×10

Invite

M. Filipits — researcher profile on SciRah